Mexico
leans on China after Biden rules out vaccines sharing in short term
Send a link to a friend
[March 10, 2021]
MEXICO CITY (Reuters) - Mexico is turning
to China to fill a vaccine shortfall with an order for 22 million doses,
Foreign Minister Marcelo Ebrard said on Tuesday, a week after U.S.
President Joe Biden ruled out sharing vaccines with Mexico in the short
term.
|
President Andres Manuel Lopez Obrador spearheaded efforts to attain
more help from China, Ebrard said.
"As a result of a process personally led by the president of the
republic, we have received the confirmation that we will have an
expansion of up to 22 million doses," Ebrard said during Lopez
Obrador's regular news conference.
Mexico's vaccine rollout has been criticized as overly slow, though
officials say they've been hampered by delays in receiving vaccines
amid global shortages.
The Biden administration appeared to have turned down Lopez
Obrador's request, at least in the short term, for the United States
to share its vaccines by saying the immediate priority is to
inoculate American citizens.
Mexico is now pinning its hopes on receiving some vaccines from the
United States once Biden meets his goal of inoculating 100 million
Americans in 100 days, a deadline due in late April.
[to top of second column] |
Ebrard said Mexico has placed
an order for an additional 10 million doses of
China's Sinovac COVID-19 vaccine to be delivered
between May and July, on top of the 10 million
already ordered, which are due to arrive between
March and May. Three million
doses of China's CanSino Biologics Inc COVID-19 vaccine are set to
arrive in Mexico on Wednesday and will be sent to Queretaro state
where they will be packaged, Ebrard said in a Tweet.
Mexico will also order 12 million vaccine doses made by the
state-backed China National Pharmaceutical Group (Sinopharm) once it
has been approved by its health regulator, Ebrard added.
(Writing by Drazen Jorgic; Editing by Kenneth Maxwell)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |